PNC Financial Services Group Inc. Has $2.81 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

PNC Financial Services Group Inc. raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 39,014 shares of the medical equipment provider’s stock after acquiring an additional 1,853 shares during the period. PNC Financial Services Group Inc.’s holdings in Hologic were worth $2,813,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. General Partner Inc. acquired a new position in shares of Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment raised its position in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares in the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Up 0.0 %

HOLX opened at $60.71 on Friday. The firm’s fifty day moving average is $67.18 and its two-hundred day moving average is $74.71. The firm has a market cap of $13.62 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a twelve month low of $60.33 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

HOLX has been the topic of several research reports. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Royal Bank of Canada reduced their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Morgan Stanley lowered their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Wolfe Research began coverage on shares of Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Finally, Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.